These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 36931947)

  • 1. Newer modalities in the management of Alzheimer's dementia along with the role of aducanumab and lecanemab in the treatment of its refractory cases.
    Marsool MDM; Prajjwal P; Reddy YB; Marsool ADM; Lam JR; Nandwana V
    Dis Mon; 2023 May; 69(5):101547. PubMed ID: 36931947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
    Terao I; Kodama W
    Ageing Res Rev; 2024 Feb; 94():102203. PubMed ID: 38253184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
    Terao I; Kodama W
    J Alzheimers Dis; 2024; 98(3):825-835. PubMed ID: 38461503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.
    Kurkinen M
    Adv Clin Exp Med; 2023 Sep; 32(9):943-947. PubMed ID: 37676096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling lecanemab as a treatment option for Alzheimer's disease.
    Schiller ER; Silverglate BD; Grossberg GT
    Expert Rev Neurother; 2024 May; 24(5):433-441. PubMed ID: 38566584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab.
    Shi M; Chu F; Zhu F; Zhu J
    Front Aging Neurosci; 2022; 14():870517. PubMed ID: 35493943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review on advances of treatment modalities for Alzheimer's disease.
    Se Thoe E; Fauzi A; Tang YQ; Chamyuang S; Chia AYY
    Life Sci; 2021 Jul; 276():119129. PubMed ID: 33515559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.
    Sheikh M; Khan SJ; Butt HAT; Zaidi SAT; Na V
    Cureus; 2023 Oct; 15(10):e47251. PubMed ID: 38021811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD Trial.
    Tahami Monfared AA; Ye W; Sardesai A; Folse H; Chavan A; Aruffo E; Zhang Q
    Neurol Ther; 2023 Jun; 12(3):863-881. PubMed ID: 37009976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
    Söderberg L; Johannesson M; Nygren P; Laudon H; Eriksson F; Osswald G; Möller C; Lannfelt L
    Neurotherapeutics; 2023 Jan; 20(1):195-206. PubMed ID: 36253511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.
    Varadharajan A; Davis AD; Ghosh A; Jagtap T; Xavier A; Menon AJ; Roy D; Gandhi S; Gregor T
    J Neurosci Rural Pract; 2023; 14(4):566-573. PubMed ID: 38059250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.
    Cohen S; van Dyck CH; Gee M; Doherty T; Kanekiyo M; Dhadda S; Li D; Hersch S; Irizarry M; Kramer LD
    J Prev Alzheimers Dis; 2023; 10(4):771-777. PubMed ID: 37874099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
    Mukhopadhyay S; Banerjee D
    J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of lecanemab for the treatment of Alzheimer's disease: A systematic review.
    Hossain MF; Husna AU; Kharel M
    Brain Behav; 2024 Jun; 14(6):e3592. PubMed ID: 38867460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives.
    Usman MB; Bhardwaj S; Roychoudhury S; Kumar D; Alexiou A; Kumar P; Ambasta RK; Prasher P; Shukla S; Upadhye V; Khan FA; Awasthi R; Shastri MD; Singh SK; Gupta G; Chellappan DK; Dua K; Jha SK; Ruokolainen J; Kesari KK; Ojha S; Jha NK
    J Prev Alzheimers Dis; 2021; 8(4):534-551. PubMed ID: 34585229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?
    Beveridge J; Kaniecki E; Naidu A; Silverglate BD; Grossberg G
    Expert Opin Emerg Drugs; 2024 Mar; 29(1):35-43. PubMed ID: 38193477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Major Hypotheses of Alzheimer's Disease: Related Nanotechnology-Based Approaches for Its Diagnosis and Treatment.
    Cáceres C; Heusser B; Garnham A; Moczko E
    Cells; 2023 Nov; 12(23):. PubMed ID: 38067098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.